A first-of-a-kind therapy that inhibits a population of T cells proved active and safe in a phase 3 trial for moderate to ...

The most common form of eczema, known as atopic dermatitis, is characterized by persistent itching, dryness, and inflammation that can flare up periodically. When dermatologists talk about eczema ...

Researchers studied the relationship between 3 dermatological immune-mediated inflammatory diseases and COVID-19.

Soothing eczema involves hydration, avoiding triggers, and stress management. Dermatology-approved treatments and following gentle skincare tips can help control symptoms and promote healthier, ...

Upadacitinib demonstrates early and sustained effectiveness up to 1 year in patients with moderate to severe atopic dermatitis in a real-world study.

Eczema, also known as atopic dermatitis, is a common skin condition that affects millions of people worldwide. It is characterized by red, itchy, and inflamed skin, and can be a source of discomfort ...

A research review found that people with skin conditions like eczema tend to have less vitamin E in their blood. A different study linked vitamin E consumption to a lower risk of developing atopic ...

Treatment-experienced patients with moderate to severe atopic dermatitis attained higher efficacy rates on rocatinlimab ...

Guttman-Yassky received research support, consulting, or lecture fees on atopic dermatitis from Regeneron, Sanofi, Pfizer, ...

Tralokinumab is effective in severe atopic dermatitis for up to 18 months, with patients who are naïve to some medications having faster benefits.

Dupilumab is safe and efficacious for the treatment of atopic dermatitis for 3 years among pediatric patients aged 6 months to 11 years.